BBR Partners LLC Purchases New Holdings in Metagenomi, Inc. (NASDAQ:MGX)

BBR Partners LLC purchased a new position in shares of Metagenomi, Inc. (NASDAQ:MGX) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 53,403 shares of the company’s stock, valued at approximately $193,000. BBR Partners LLC owned about 0.14% of Metagenomi as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. BNP Paribas Financial Markets grew its holdings in Metagenomi by 130.9% during the third quarter. BNP Paribas Financial Markets now owns 12,799 shares of the company’s stock worth $28,000 after purchasing an additional 7,256 shares during the period. Virtu Financial LLC bought a new position in shares of Metagenomi during the 3rd quarter worth approximately $33,000. Rhumbline Advisers increased its holdings in shares of Metagenomi by 123.3% during the 4th quarter. Rhumbline Advisers now owns 11,998 shares of the company’s stock worth $43,000 after acquiring an additional 6,626 shares during the last quarter. SG Americas Securities LLC acquired a new stake in Metagenomi during the 4th quarter valued at $43,000. Finally, Verition Fund Management LLC bought a new position in Metagenomi during the third quarter worth $82,000.

Metagenomi Price Performance

MGX opened at $2.07 on Friday. The stock has a fifty day moving average of $2.68 and a 200-day moving average of $2.57. Metagenomi, Inc. has a fifty-two week low of $1.61 and a fifty-two week high of $12.10.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. HC Wainwright increased their price objective on shares of Metagenomi from $7.00 to $14.00 and gave the company a “buy” rating in a research report on Tuesday, December 10th. Chardan Capital restated a “buy” rating and set a $15.00 price objective on shares of Metagenomi in a research report on Wednesday, November 20th.

Metagenomi Company Profile

Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.